Pancreatic Cancer Drug Rasonque Shows Early Promise Against RAS‑Mutated Lung Cancer Too
Investigators will discontinue their assessment of eftilagimod alfa (efti) in combination with pembrolizumab (Keytruda) and chemotherapy among patients with first‑line non‑small cell lung cancer (NSCLC) as part of the phase 3 TACTI‑004 trial (NCT06726265).
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT